Dianthus EVP exercises options, sells 33,830 shares

Dianthus Therapeutics EVP and Head of R&D Simrat Randhawa exercised stock options for 33,830 shares of common stock and sold 33,830 shares in an open-market transaction.

Accepted by SEC EDGAR 03/13/2026 - 08:30 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Dianthus Therapeutics EVP and Head of R&D Simrat Randhawa exercised stock options for 33,830 shares of common stock and sold 33,830 shares in an open-market transaction. The sale was executed at a price of $81.48 per share and made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025. Following these transactions, Randhawa held no shares of common stock directly, according to the filing.

Insider Trade Summary 10b5-1

Exercise and Sale: 33,830 shares ($2.14M approx. pre-tax spread)

Exercise and Sale 9 txns

Insider Randhawa Simrat

Role EVP, Head of R&D

Sold 33,830 shs ($2.76M)

Approx. gross sale proceeds $2.76M

Approx. exercise cost $614K

Approx. pre-tax spread $2.14M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	7,998	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	5,000	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	8,332	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	12,500	$0.00	$0.00
Exercise	Common Stock	7,998	$8.44	$68K
Exercise	Common Stock	5,000	$17.88	$89K
Exercise	Common Stock	8,332	$21.77	$181K
Exercise	Common Stock	12,500	$22.07	$276K
Sale	Common Stock	33,830	$81.48	$2.76M

Holdings After Transaction: Stock Option (Right to Buy) — 235,606 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (5)

F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025.
F2. The shares of common stock underlying this stock option award vested as to 25% of the shares on April 25, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
F3. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
F4. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
F5. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Simrat Randhawa report for Dianthus Therapeutics (DNTH)?

Simrat Randhawa reported exercising stock options covering 33,830 Dianthus Therapeutics shares and selling 33,830 common shares. These transactions reflect an exercise-and-sell pattern, where options are converted into stock and then fully sold in the market on the same date.

At what price did Simrat Randhawa sell Dianthus Therapeutics (DNTH) shares?

Randhawa sold 33,830 shares of Dianthus Therapeutics common stock at $81.48 per share. The sale occurred in an open-market transaction on the same date as the option exercises, consolidating the derivative position into cash rather than retaining the acquired shares.

Were Simrat Randhawa’s DNTH stock transactions under a Rule 10b5-1 trading plan?

Yes. The filing states the reported transaction was effected under a Rule 10b5-1 trading plan adopted on August 14, 2025. Such plans pre-schedule trades, indicating the timing of this exercise-and-sale sequence was determined in advance rather than chosen opportunistically.

How many Dianthus Therapeutics (DNTH) options did Simrat Randhawa exercise?

Randhawa exercised stock options covering a total of 33,830 shares of Dianthus Therapeutics common stock. The options carried various exercise prices, including $8.44, $17.88, $21.77 and $22.07 per share, and were converted into common shares before being sold.

What was Simrat Randhawa’s direct DNTH common stock holding after these transactions?

After the reported transactions, Randhawa held zero shares of Dianthus Therapeutics common stock directly. The filing’s ownership table shows total shares of common stock following the open-market sale as 0, indicating the newly acquired shares from the option exercises were fully disposed.

What role does Simrat Randhawa hold at Dianthus Therapeutics (DNTH)?

Simrat Randhawa serves as Executive Vice President and Head of R&D at Dianthus Therapeutics. The position is disclosed in the insider report, which identifies Randhawa as an officer, providing context for the reported option exercises and subsequent sale of company shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Randhawa Simrat

(Last)

(First)

(Middle)

C/O DIANTHUS THERAPEUTICS, INC.

7 TIMES SQUARE, 43RD FLOOR

(Street)

NEW YORK

10036

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Dianthus Therapeutics, Inc. /DE/ [ DNTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Head of R&D

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/12/2026		M⁽¹⁾		7,998	A	$8.44	7,998	D
Common Stock	03/12/2026		M⁽¹⁾		5,000	A	$17.88	12,998	D
Common Stock	03/12/2026		M⁽¹⁾		8,332	A	$21.77	21,330	D
Common Stock	03/12/2026		M⁽¹⁾		12,500	A	$22.07	33,830	D
Common Stock	03/12/2026		S⁽¹⁾		33,830	D	$81.48	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$8.44	03/12/2026		M⁽¹⁾			7,998	⁽²⁾	06/06/2032	Common Stock	7,998	$0	3,998	D
Stock Option (Right to Buy)	$17.88	03/12/2026		M⁽¹⁾			5,000	⁽³⁾	01/23/2034	Common Stock	5,000	$0	71,184	D
Stock Option (Right to Buy)	$21.77	03/12/2026		M⁽¹⁾			8,332	⁽⁴⁾	05/22/2034	Common Stock	8,332	$0	54,174	D
Stock Option (Right to Buy)	$22.07	03/12/2026		M⁽¹⁾			12,500	⁽⁵⁾	02/03/2035	Common Stock	12,500	$0	106,250	D

Explanation of Responses:

1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025.

2. The shares of common stock underlying this stock option award vested as to 25% of the shares on April 25, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

3. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

4. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

5. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

	/s/ Adam Veness, as attorney-in-fact for Simrat Randhawa	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR